10 / 10
Page 47
June 10-11, 2019 | Edinburgh, Scotland
Central Nervous System and Therapeutics
2
nd
International Conference on
Journal of Neurology and Neurorehabilitation Research | Volume 4
allied
academies
Changing the Game: A New Class of Anti-Migraine Drugs
Teena Shetty
Concussion Program at HSS, USA
Background:
Migraine headaches are a severe and disabling
neurovascular disorder affecting nearly 20% of adults in the
United States1. Calcitonin Gene Related Peptide (CGRP)
monoclonal antibodies (mAB) is a new class of anti-migraine
drugs that represent the first targeted therapy for the
prevention of migraine.
Methods:
There are currently only 3 manufacturers with
FDA approved CGRP mABs. Both Emgality (Eli Lilly) and
Ajovy (Fremanezumab) target the CGRP ligand whereas
Aimovig (Amgen) targets the CGRP receptor. All drugs have
been tested independently in studies of episodic and chronic
migraine. The safety and efficacy of these study drugs will be
reviewed.
Results:
All three FDA approved drugs show similar efficacy
and safety profiles. Aimovig and Emgality reported a mean
difference from placebo in reduction of headache days for
episodic migraines of 1.9 days compared to 1.5 days for
Ajovy.2-4 Change in mean difference was greater for studies
of chronic migraine at 2.5, 2.1 and 2.1 days, respectively.5-7
Further data from a 5-year open-label extension study of
Aimovig demonstrates its long-term efficacy with 67% of
patients experiencing ≥50% reduction in chronic monthly
migraines.4 Data also suggests that CGRP inhibitors may
have greater efficacy in patients who have failed 1 or more
preventative medications.4
Conclusions:
Evidence to date suggests that overall, CGRP
targeted therapies for the prevention of a variety of headache
disorders represent a new series of drugs that are powerful
and effective. CGRP anti-migraine drugs have favorable
treatment profiles similar to those of placebo and have the
potential to treat migraine sufferers with treatment resistant
headaches.
e
:teena_shetty@yahoo.comNotes: